Phase 2 of new ARVs

Bictegravir
BIC Phase 2 Study: BIC + FTC/TAF vs DTG + FTC/TAF
Original article : Sax PE. Lancet HIV 2017; 4:e154-e160
Last update : 29/03/2017

Dr Anton Pozniak
Chelsea and Westminster Hospital
London, UK

Design :


BIC: 75 mg QDµ
DTG: 50 mg QD

Objective :

  • % HIV RNA < 50 c/mL at W24

Baseline characteristics and patient disposition

HIV RNA < 50 c/ml (ITT, snapshot )

CD4 increase at W48 (mean)

  • BIC: + 258/mm3 vs DTG: + 192/mm3

Adverse events, %

  • 1 patient in the BIC + FTC/TAF group with a past history of urticaria and atopic dermatitis discontinued study drug after W24 due to urticaria
 

Back to Table of Contents

Copyright AEI 2017 | Links | Contact | Faculty and Disclosure | Terms of use aei